What is the quality of Quizartinib produced in India?

Quizartinib (Quizartinib) is a targeted treatment drug for FLT3 mutated acute myeloid leukemia. Its original version has been approved for marketing in some countries in Europe, America and Asia. However, in the Indian market, although the country is an important base for global generic drug manufacturing, there is still no local pharmaceutical company that has launched the original research or generic version of Quizartinib. This phenomenon is closely related to pharmaceutical intellectual property protection policies, market demand assessment and technical barriers.

In India, many high-priced imported anti-cancer drugs are quickly imitated by generic drug manufacturers to meet domestic and foreign demand. However, Quizartinib has not yet entered this process, mainly because its original drug is still under patent protection worldwide, and its production involves high compound stability and manufacturing complexity. In addition, the Indian drug regulatory agency's approval standards for generic drugs have been continuously improved in recent years, requiring equivalence studies, stability data and complete drug registration documents, which also makes generic manufacturers more cautious when launching new products.

From a market perspective, the main indication for Quizartinib is FLT3-ITD mutant AML. The proportion of patients with this type of disease is relatively low in acute myeloid leukemia. Therefore, whether there is sufficient market volume in India to support the development of generic drugs may also be one of the factors that pharmaceutical companies wait and see. At the international level, since patients often obtain original drugs through cross-border medical treatment or third-party channels, local production is not as urgent as other anti-cancer drugs.

However, India’s technological strength in the field of generic drugs cannot be underestimated. Once the patent period of Quizartinib is about to end, it is not ruled out that large pharmaceutical companies will quickly launch lower-priced generic versions to meet the treatment needs of low- and middle-income countries in South Asia and even the world. At the same time, if the Indian government includes it in the priority drug list, it may also accelerate the development and marketing of the local version.

Reference materials:https://go.drugbank.com/drugs/DB12874